A randomized, open-label, multi-center phase III study of durvalumab and tremelimumab as first-line treatment in patients with advanced hepatocellular carcinoma. NCT03298451
Abou-Alfa GK et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379(1):54-63. Abstract
Brown ZJ et al. Adjuvant treatment of hepatocellular carcinoma: Prospect of immunotherapy. Hepatology 2019;70(4):1437-42. Abstract
Brown ZJ et al. Development of shellfish allergy after exposure to dual immune checkpoint blockade. Hepat Oncol 2018;5(1):HEP02. Abstract
Bruix J et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389(10064):56-66. Abstract
Cheng A-L et al. IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). ESMO 2019;Abstract LBA3.
Chow PKH et al. SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 2018;36(19):1913-21. Abstract
El-Khoueiry AB et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389(10088):2492-502. Abstract
Finn RS et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. J Clin Oncol 2020;38(3):193-202. Abstract
Floudas CS et al. Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC). Gastrointestinal Cancers Symposium 2019;Abstract 336.
Floudas CS et al. Immunotherapy: Current status and future perspectives. Dig Dis Sci 2019;64(4):1030-40. Abstract
Galle PR et al. Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Gastrointestinal Cancers Symposium 2020;Abstract 476.
Greten TF et al. Combined locoregional-immunotherapy for liver cancer. J Hepatol 2019;70(5):999-1007. Abstract
Greten TF et al. Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology 2019;156(2):510-24. Abstract
He AR et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040. Gastrointestinal Cancers Symposium 2020;Abstract 512.
Kelley RK et al. Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. ASCO 2019;Abstract TPS4157.
Kudo M et al. Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. ASCO 2019;Abstract 327.
Kudo M et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 2018;391(10126):1163-73. Abstract
Lemery S et al. First FDA approval agnostic of cancer site — When a biomarker defines the indication. N Engl J Med 2017;377(15):1409-12. Abstract
Yau T et al. Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. Gastrointestinal Cancers Symposium 2020;Abstract 478.
Zhu AX et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19(7):940-52. Abstract